-
Factors Impacting GKV Rebates for Orphan Drugs (OD) in Germany: A Decision Analysis Using the CRA RADAR Database
Sep 9, 2025, 16:22 PM -
Systematic Review of Effectiveness of SGLT2 Inhibitors in Patients With Type 2 Diabetes With Focus on Glucose Levels, Cardiovascular Events, and Renal Function
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Familial Hypercholesterolemia Cascade Testing in Thailand: A Comparative Analysis of Exome vs. Long-Read DNA Sequencing
Sep 9, 2025, 16:22 PM -
Pharmacoeconomic and Healthcare Aspects of the TDM-Guided Decisions on Biological Treatment of Inflammatory Diseases: Systematic Review of International Evidence
Sep 9, 2025, 16:22 PM -
How Publication Bias May Overestimate the Risk of Serious Adverse Events Associated With Bisphosphonate Use
Sep 9, 2025, 16:22 PM -
Potential Implications of EU Joint Clinical Assessment (JCA) for the UK Affiliate of a Global Pharmaceutical Company
Sep 9, 2025, 16:22 PM -
Budget Impact and Clinical Outcomes of Energy- and Nutrient-Dense Formulas in Pediatric Disease-Related Malnutrition: A Middle Eastern Analysis
Sep 9, 2025, 16:22 PM -
Optimal Utilization of Robotic-Assisted Surgery in the NHS: A System-Level Economic Evaluation Model
Sep 9, 2025, 16:22 PM -
Preliminary Observational Analysis of Digital Health Platform Associated With Medical Cost Changes in Employer Population
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Iptacopan for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With C5 Inhibitor in the Brazilian Private Healthcare System
Sep 9, 2025, 16:22 PM -
Implementation and Outcomes of Managed Entry Agreements Across the Nordic Region
Sep 9, 2025, 16:22 PM -
Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada
Sep 9, 2025, 16:22 PM -
From Policy to Practice: Are Larger Member States Leading the Way for Joint Clinical Assessments?
Sep 9, 2025, 16:22 PM -
Implications of Recent US Policy Changes on Evidence Generation Requirements for Enabling Access to Medicines and Vaccines in Low- and Middle-Income Countries
Sep 9, 2025, 16:22 PM -
Societal Impact Analysis of Introducing Elexacaftor Tezacaftor Ivacaftor (ELX TEZ IVA) in the Management of People With Cystic Fibrosis in Germany: A Paid and Unpaid Work Productivity Approach
Sep 9, 2025, 16:22 PM -
Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France
Sep 9, 2025, 16:22 PM -
Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025
Sep 9, 2025, 16:22 PM -
Clinical Profile of Asthma and Its Geographical Variability in Southern Spain
Sep 9, 2025, 16:22 PM -
A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of the EPOCA Telemonitoring System for Elderly Patients in France
Sep 9, 2025, 16:22 PM
